Healthcare & Life Sciences
Pharma, medical devices, care delivery, diagnostics, and health services. This page compares reported financial scale with the customer needs and operating signals that shape sector performance.
- Companies
- 121
- Average revenue
- $31.2B
- Average margin
- 4.2%
- Average growth
- 10.8%
What this industry is really competing to solve
Demand emerges when patients and professionals need better outcomes with less risk, pain, delay, or uncertainty. The deeper motives are survival, safety, dignity, autonomy, and hope. This is why the competitive set extends beyond companies with the same industry code.
Customers can also choose standard of care, generics, alternative therapies, watchful waiting, prevention, and non-treatment. Industry growth becomes durable only when companies make the desired progress easier than those alternatives.
How demand becomes profit and cash
The common mechanism is turning clinical evidence, access, adherence, and professional trust into treated patients and durable economics. Across the industry, the decisive investment question is whether research, capacity, and access investment expands treated demand before patent, reimbursement, or safety risk erodes value.
Average operating profit is $2.1B, but the spread between leaders and laggards matters more than the average alone. Compare scale, margin, growth, and the leading indicators together.
Healthcare & Life Sciences companies
| Company | Revenue | Operating profit | Margin | Growth |
|---|---|---|---|---|
| Acadia Pharmaceuticals ACAD | $1.1B | $105M | 9.8% | +11.9% |
| Tandem Diabetes Care TNDM | $1B | -$187M | -18.4% | +8.0% |
| Guardant Health GH | $982M | -$437M | -44.5% | +32.9% |
| CorVel CRVL | $959M | $110M | 11.5% | +7.0% |
| Ionis Pharmaceuticals IONS | $944M | -$382M | -40.5% | +33.9% |
| Inspire Medical Systems INSP | $912M | $51M | 5.6% | +13.6% |
| Neogen NEOG | $895M | -$1.1B | -118.5% | -3.1% |
| U.S. Physical Therapy USPH | $781M | $87M | 11.1% | +16.4% |
| Corcept Therapeutics CORT | $761M | $100M | 13.1% | +12.7% |
| iRhythm Technologies IRTC | $747M | -$57M | -7.6% | +26.2% |
| Repligen RGEN | $738M | $55M | 7.5% | +16.4% |
| Avanos Medical AVNS | $701M | -$62M | -8.8% | +1.9% |
| Ultragenyx Pharmaceutical RARE | $673M | -$535M | -79.5% | +20.2% |
| Novocure NVCR | $655M | -$154M | -23.5% | +8.3% |
| Doximity DOCS | $645M | $215M | 33.3% | +13.2% |
| TransMedics Group TMDX | $605M | $109M | 18.0% | +36.9% |
| AtriCure ATRC | $535M | -$9M | -1.7% | +15.1% |
| Veracyte VCYT | $517M | $58M | 11.2% | +15.9% |
| Glaukos GKOS | $507M | -$200M | -39.4% | +32.4% |
| Inogen INGN | $349M | -$30M | -8.6% | +3.9% |
| Health Catalyst HCAT | $311M | -$161M | -51.8% | +1.3% |
| PROCEPT BioRobotics PRCT | $308M | -$104M | -33.8% | +37.5% |
| Talkspace TALK | $229M | $3M | 1.3% | +21.8% |
| Outset Medical OM | $119M | -$67M | -56.3% | +4.4% |
| Simulations Plus SLP | $79M | -$71M | -89.9% | +12.9% |
